Baseline Levels of Immune Phenotypes and Plasma Biomarkers (N=434)
| Measurement | Analysis Cohort (n=436) |
Excluded* (n=255) |
p-value | ||
|---|---|---|---|---|---|
| Monocyte Phenotypes | Median (IQR) | Median (IQR) | |||
| CD14+/CD16−, % | 78.8 | (71.4, 83.8) | 80.0 | (73.4, 83.9) | 0.14 |
| CD14+/CD16+, % | 5.2 | (3.3, 7.6) | 5.4 | (3.5, 8.4) | 0.19 |
| CD14dim/CD16+, % | 6.6 | (3.8, 10.6) | 5.6 | (3.6, 9.6) | 0.12 |
| CD14var/CD16+, % | 12.7 | (8.4, 18.5) | 11.9 | (8.3, 17.2) | 0.53 |
| TF+, % | 1.6 | (0.9, 3.2) | 1.4 | (0.8, 3.0) | 0.37 |
| CCR2+, % | 88.9 | (82.9, 93.4) | 89.6 | (84.7, 93.5) | 0.19 |
| CCR5+, % | 4.3 | (2.1, 9.6) | 4.8 | (2.2, 8.2) | 0.91 |
| CX3CR1+, % | 7.5 | (3.6, 12.4) | 6.9 | 3.6, 10.9) | 0.52 |
| T-cell Phenotypes | |||||
| CD4+/HLADR+/CD38+, % | 7.6 | (4.4, 13.8) | 8.3 | (4.8, 14.9) | 0.09 |
| CD4+/CD57+/CD38+, % | 3.8 | (1.7, 8.2) | 3.0 | (1.5, 8.0) | 0.55 |
| CD4+/CD57+, % | 7.5 | (3.4, 14.7) | 7.3 | (3.2, 15.9) | 0.89 |
| CD4+/CX3CR1+, % | 2.6 | (0.9, 6.3) | 2.7 | (0.7, 5.3) | 0.56 |
| CD8+/HLADR+/CD38+, % | 19.8 | (11.3, 33.9) | 22.9 | (12.1, 35.6) | 0.13 |
| CD8+/CD57+/CD38+, % | 22.1 | (13.2, 31.3) | 22.6 | (14.3, 29.9) | 0.91 |
| CD8+/CD57+, % | 34.6 | (26.2, 44.4) | 33.4 | (26.7, 43.3) | 0.37 |
| CD8+/CX3CR1+, % | 18.9 | (10.3, 31.4) | 17.0 | (9.4, 28.3) | 0.15 |
|
Soluble Plasma Biomarkers |
|||||
| hsCRP, mg/dL | 1.75 | (0.79, 4.25) | 1.91 | (0.82, 4.94) | 0.43 |
| IL-6, pg/mL | 1.05 | (0.68, 1.66) | 1.11 | (0.72, 1.70) | 0.29 |
| sCD14, µg/mL | 1146 | (962, 1390) | 1137 | (917, 1348) | 0.43 |
| sCD163, ng/mL | 539 | (372, 788) | 523 | (368, 802) | 0.69 |
| D-dimer, µg/mL | 0.12 | (0.05, 0.24) | 0.14 | (0.06, 0.24) | 0.43 |
*
SUN Study participants excluded from analysis cohort included those missing CAC measures at baseline or year 2.
P-value for difference in the distribution given parameter between groups by Wilcoxon rank sum test.
TF = tissue factor; hsCRP = high sensitivity C-reactive protein; IL-6 = interleukin-6.